HealthcareServices

Cholangiocarcinoma Industry Forecast to Hit $1.02 Billion by 2029 With a Strong 13% CAGR

November 27, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Future Market Size Estimation For The Cholangiocarcinoma Market Covering 2025–2034?

The cholangiocarcinoma market has experienced rapid expansion in recent years. Its value is anticipated to rise from $0.55 billion in 2024 to $0.62 billion in 2025, achieving a compound annual growth rate (CAGR) of 13.1%. This historic growth can be ascribed to several factors, including the increasing occurrence of liver and bile duct cancers, enhanced understanding of rare cancers, a heightened focus on individualized treatment plans, an increase in immunotherapy applications, and an expanding elderly demographic.

The cholangiocarcinoma market is projected for substantial expansion over the coming years. Its valuation is anticipated to reach $1.02 billion by 2029, showcasing a compound annual growth rate (CAGR) of 13.0%. This projected growth is driven by factors such as the increasing adoption of precision medicine, rising healthcare expenditure, a greater prevalence of genetic testing, and the expanding popularity of retail pharmacies. Significant trends in the forecast period include advancements in diagnostic methods, the growth of clinical trials, the integration of AI in diagnostics, improvements in drug delivery systems, and continued drug development.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21139&type=smp

What Are The Top Growth Drivers Impacting The Cholangiocarcinoma Market Outlook?

The escalating occurrence of liver disease is anticipated to boost the growth of the cholangiocarcinoma market moving forward. Liver disease refers to conditions that impair the liver’s normal function or structure, such as hepatitis, cirrhosis, fatty liver disease, and liver cancer. The prevalence of liver disease is increasing due to rising risk factors like obesity, diabetes, alcohol consumption, and viral hepatitis infections. Liver disease, particularly its chronic inflammation and cirrhosis forms, heightens the risk of cholangiocarcinoma by encouraging bile duct damage and malignant cellular transformation. For instance, in December 2024, the Office for Health Improvement and Disparities, a UK-based government agency, reported that premature deaths attributable to alcoholic liver disease in 2023 increased by 3.6% to 5,984, up from 5,776 in 2022. Thus, the growing incidence of liver disease is a key driver for expansion in the cholangiocarcinoma market.

What Are The Leading Segments Analyzed In The Cholangiocarcinoma Market?

The cholangiocarcinomamarket covered in this report is segmented –

1) By Cancer: Intrahepatic Cholangiocarcinoma; Extrahepatic Cholangiocarcinoma

2) By Product: Capecitabine; 5-Fluorouracil; Oxaliplatin; Gemcitabine; Cisplatin

3) By Therapy: Targeted Drug Therapy; Chemotherapy; Immunotherapy

4) By Route Of Administration: Oral; Subcutaneous; Intravenous

5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; E-Commerce

Subsegments:

1) By Intrahepatic Cholangiocarcinoma: Peripheral Intrahepatic Cholangiocarcinoma; Mass-Forming Intrahepatic Cholangiocarcinoma

2) By Extrahepatic Cholangiocarcinoma: Perihilar Cholangiocarcinoma; Distal Cholangiocarcinoma

Which Key Trends Are Expected To Influence The Cholangiocarcinoma Market In The Coming Years?

Leading companies within the cholangiocarcinoma market are concentrating on developing innovative treatments, such as targeted therapies, to enhance patient outcomes. Targeted therapies are specifically designed to home in on particular genes, proteins, or molecules that assist cancer cell growth. These treatments function by blocking the mechanisms that enable cancer to proliferate, with the goal of arresting tumor growth, mitigating side effects, and improving overall treatment results. As an illustration, in August 2023, Taiho Pharmaceutical Co. Ltd., a pharmaceutical company based in Japan, introduced LYTGOBI (futibatinib), an FGFR inhibitor, for use in treating unresectable biliary tract cancer that has FGFR2 gene fusions. Its design allows it to selectively and irreversibly inhibit FGFR signaling, which contributes to slowing tumor growth and improving outcomes for patients with cholangiocarcinoma (iCCA) whose condition has worsened after chemotherapy.

Which Key Market Players Are Investing In Expansion And Innovation Of Cholangiocarcinoma Market?

Major companies operating in the cholangiocarcinoma market are F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boston Scientific Corporation, Servier Laboratories, Incyte Corporation, Exelixis Inc., Hutchison China MediTech Limited, Zymeworks Inc., Agios Pharmaceuticals Inc., RenovoRx Inc., Specialised Therapeutics Pty Ltd, Ascletis Pharma Inc., Tiziana Life Sciences Ltd., Taiho Pharmaceutical Co. Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/cholangiocarcinoma-global-market-report

How Does The Cholangiocarcinoma Market Perform Across Key Geographic Regions?

North America was the largest region in the cholangiocarcinoma market in 2024. The regions covered in the cholangiocarcinoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Cholangiocarcinoma Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21139&type=smp

Browse Through More Reports Similar to the Global Cholangiocarcinoma Market 2025, By The Business Research Company

Cancer Biologics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Skin Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/skin-cancer-drugs-global-market-report

Pancreatic Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795